Enzo Announces Settlement with Sigma-Aldrich in Contract and Patent Litigation
Complete the form below to unlock access to ALL audio articles.
Enzo Biochem, Inc. has announced that it has reached a settlement with Sigma-Aldrich Corp.
Sigma was the defendant in a suit brought by Enzo alleging, among other things, breach of contract and infringement of patents related to the Company's proprietary labeled nucleotide technology.
The settlement agreement followed the recent Markman Hearing ruling by a Federal Court Judge in the Southern District of New York relating to claim terms in eight patents asserted against Sigma.
"Enzo is pleased to have settled with Sigma-Aldrich on favorable terms. Sigma is the first defendant to settle in the various actions brought by Enzo," the Company said.
"Additional defendants in the various actions include Affymetrix Inc., Roche Diagnostics, Amersham Biosciences, Inc., Perkin Elmer, Inc., Orchid Biosciences, Inc. and Molecular Probes, Inc. We continue to aggressively pursue our claims with respect to the remaining defendants."
Enzo is represented in the litigations by Greenberg Traurig, LLP.
